The overall market of idiopathic pulmonary fibrosis is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging therapy for idiopathic pulmonary fibrosis treatment, will boost the idiopathic pulmonary fibrosis market in the forecasted period (2023–2032).New York, USA, Oct. 30, 2023 (GLOBE NEWSWIRE) Idiopathic Pulmonary Fibrosis Market to Show Immense Growth at a CAGR of 6.6% During the Study Period (2019–2032) |
Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Suzhou, October 11, 2023 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its.
Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma